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Background: Pre-clinical studies have shown that hypoxia preconditioning can enhance stem cell therapeutic po-
tential for myocardial repair. We sought to investigate the safety and feasibility of intracoronary administration
of hypoxia-preconditioned bone marrowmononuclear cells (HP-BMCs) for acute ST segment elevation myocar-
dial infarction (STEMI).
Methods: We randomized 22 patients with acute STEMI to receive intracoronary administration of normoxia
bonemarrowmononuclear cells (N-BMCs) (n= 11) or HP-BMCs (n= 11) following successful reperfusion. An-
other 14 patients receiving standard therapy were recruited as control (n = 14).
Results: Therewere no differences in the occurrence ofmajor adverse cardiovascular events at 30 days and 1 year
among three groups. There were significant improvement in the change of left ventricular end-diastolic volume
(LVEDV) and end-systolic volume (LVESV) inHP-BMC group both at 6 and 12months comparedwith N-BMCs or
control group (P b 0.05). No differences were observed in the change of left ventricular ejection fraction (LVEF),
or wall motion score index (WMSI) among three groups. Nevertheless, WMSI was improved in HP-BMCs and N-
BMC group (P b 0.05, within group), but not in control. The ratio of myocardial perfusion defect determined by
SPECT was significantly decreased in HP-BMCs and N-BMC groups at 6 months compared with baseline
(P b 0.05, within group), but no significant differences were observed among three groups.
Conclusions:Our results provide the first-in-man evidence that intracoronary administration of HP-BMCs follow-
ing acute MI appears to be safe and feasible. These results provide the basis for future prospective randomized
clinical trials in a larger patient cohort.
Clinical trial registration information: NCT01234181 (http://clinicaltrials.gov/ct2/show/NCT01234181?term=
NCT01234181&rank=1).
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autologous bonemarrowmononuclear cell (BMC) administration has
been investigated as a potential novel therapy to improve left ventricular
(LV) function, reverse remodeling and reduce myocardial scarring ingy, Second Affiliated Hospital,
Hangzhou 310009, PR China.
land Ltd. This is an open access articlpatients with acutemyocardial infarction (MI) [1]. Nevertheless some re-
cent randomized controlled trials [2,3] andmeta-analysis [4,5] have failed
to demonstrate any consistent improvement in LV function or infarct size.
This highlights the need for adjunctive strategies to further enhance the
therapeutic efficacy of current stem cell therapy for acuteMI. Prior exper-
imental studies suggest that poor cell engraftment and survival of the
transplanted BMCs are major hurdles to the development of effective
cell-based therapy [6-8]. Exposure of the stemcells to lowoxygen tension,
i.e., hypoxia preconditioning, has been shown to improve survival of steme under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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myocardial repair [10]. Indeed our previous experimental studies [11,12]
demonstrated that hypoxia preconditioning enhances BMC survival, mi-
gration, and angiogenesis, and thus improves their therapeutic efficacy.
Nevertheless, there are no human data on the safety and therapeutic effi-
cacy of BMCs following hypoxia preconditioning in the treatment of acute
MI.
In this phase 1, prospective, randomized and double-blind con-
trolled trial, we sought to determine the safety and feasibility of
intracoronary administration of autologous hypoxia-preconditioned
BMCs (HP-BMCs) in patients with acute ST segment elevation MI fol-
lowing successful reperfusion.
2. Methods
2.1. Study design and patient enrollment
From February 2011 to March 2012, patients aged between 18 and
75 years old were eligible for the study if they presented with an
acute ST segment elevation MI that had been successfully reperfused
by means of primary percutaneous coronary intervention (PCI) with
stent implantation or thrombolysis; and had a substantial residual
LV regional wall motion abnormality (defined as wall motion score
index (WMSI) N 1) evident on transthoracic echocardiogram. Patients
were excluded from study if they had any of the following: life
expectancy b 1 year, sepsis, hemodynamic instability, moderate–severe
renal impairment (glomerular filtration rate b 50 mL/min/1.73 m2),
NewYorkHeart Association Class IV heart failure on intravenous inotro-
pic therapy, need for further coronary revascularization or significant
valvular heart disease. The research protocol was approved by the
Ethics Committee of Human Research of Second Affiliated Hospital of
Zhejiang University, and all participants provided written informed
consent. The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori approval by the
institution's human research committee. The protocol has been regis-
tered at ClinicalTrials.gov (Trial identifier: NCT01234181).
2.2. Study protocol
Twenty two patients were randomly assigned to the normoxia BMC
group or hypoxia-preconditioned BMC group in a 1:1 ratio using a ran-
domization number table. Patients randomized to each group received
10 × 107 BMCs that had been cultured for 24 h in a normoxic or hypoxic
environment. Another 14 patients received standard treatment as con-
trol. Patients, study coordinators, and the investigators who were re-
sponsible for patient assessment were blinded to the randomization
process. Baseline evaluation in three groups including echocardiogra-
phy and single-photon emission computed tomographic (SPECT) perfu-
sion study, performed at 3–5 days following PCI, and repeated at 6 and
12-month follow-ups. Arrhythmia was assessed after infusion, at
1 month, 6 months and 12 months using a Holter monitor.
2.3. Preparation and administration of BMCs
At day 5 after PCI, BMCs were harvested from patients by an experi-
enced doctor via posterior iliac crest puncture under local anesthetic. A
total of 80–100mL of bonemarrow bloodwas aspirated. BMCs were iso-
lated by Ficoll density gradient centrifugation as previously described [13,
14]. BMCs were washed twice in phosphate-buffered saline with 0.5%
human serum albumin. The final cell suspension contained 10 × 107
BMCs in 10 ml of saline. The BMCs were analyzed by fluorescence-
activated cell sorting using anti-CD34, anti-CD133, anti-CD309, anti-
CD117, anti-CD29, anti-CD166 and anti-mSca-1 (BD Pharmagin, San
Jose, CA). Cell viability was assessed by Trypan blue staining.
BMCs were plated on serum free culture medium (StemPro® SFM
XenoFree complete medium, GIBCO Invitrogen, Carlsbad, CA, USA) andcultured for 24 h. Normoxia BMCswere incubated under normoxic con-
ditions (37 °C, 21% O2, 5% CO2). Hypoxia preconditioning treatmentwas
achieved by placing cells in a well-characterized, finely controlled
ProOx-C-chamber system (BioSpherix, Redfield, NY, USA) for 24 h. The
O2 concentration in the chamberwasmaintained at 0.5%,with a residual
gas mixture composed of 5% CO2 and balanced N2.
BMCs were administrated using a stop-flow [15] technique through
an over-the-wire balloon catheter (Open-sail, Guidant, USA) positioned
within the stented segment of the infarct-related artery. A total of
10 × 107 normoxia or hypoxia-preconditioned BMCs were infused into
the infarct relatedmyocardium. All patients received unfractionated hep-
arin to achieve an activated clotting time N300 s during the procedure.
2.4. Study endpoint
Primary endpoint was the safety of the therapy defined by the inci-
dence of any treatment associated major adverse cardiovascular events
(MACEs) including death, nonfatal MI, stroke, heart failure hospitaliza-
tion or hemodynamic significant or sustained ventricular arrhythmias
(N15 s as detected by 24hHoltermonitoring)within 30 days of BMC in-
jection. The secondary safety endpoint included the occurrence of
MACEs within 12 months.
Pre-specified secondary efficacy endpoints were change (6-month
follow-up minus baseline) in myocardium perfusion defect ratio as de-
termined by SPECT, and global left ventricular ejection fraction (LVEF),
left ventricular end-diastolic volume (LVEDV), left ventricular end-
systolic volume (LVESV) and WMSI as measured by echocardiography.
2.5. Echocardiographic analysis
StandardM-mode, two dimensional and color Doppler echocardiog-
raphy were performed [16] by a single experienced operator who was
blinded to patients' treatment. The measurements included LVESV,
LVEDV, WMSI and LVEF. These measurements were computed using
the biplane rule methods of Simpson [17].
2.6. Cardiac SPECT scan
SPECT perfusion test was performed to identify changes in ischemic
defects at rest using a standardized protocol. In brief, 740–925 MBq (20–
25mCi) 99mTc-MIBIwas injected and gatedmyocardial SPECTperformed
60 min later using a dual-detector SPECT system (Siemens E.CAM duet)
equippedwith low-energy high-resolution collimators. The SPECT images
were gated with eight frames per cardiac cycle. Acquisition parameters
were as follows: energy window 140 keV ± 10%, 180° noncircular orbit,
5.6° per step, 64 × 64 matrix, zoom ×1.45, 40 s acquisition per step.
Transaxial slices were reconstructed via back projectionwith a ramp
filter, followed by a Butterworth filter with an order of 10 and cut-off of
0.55. Software of the Emory Cardiac Toolbox (ECTb, Emory University,
Atlanta, GA, USA) was used to create polar maps and obtain other pa-
rameters. The infarct size was expressed as a percentage of the LV. The
LVmyocardiumwas divided into 20 segments, and the ratio of myocar-
dium perfusion defect was calculated.
2.7. Statistical analysis
All statistical analyseswere conducted using SAS version 9.2 (SAS In-
stitute Inc.). Descriptive statistics for baseline characteristics were gen-
erated for demographic variables, medical history, and laboratory data.
Categorical variables were presented as frequency and percent. Contin-
uous variables (normal distribution) were presented as mean and
standard derivation or median and range (non-normal distribution).
Chi-squared and ANOVA tests were used to evaluate the differences
among 3 groups at baseline. Wilcoxon signed-rank test was used to eval-
uate the difference of non-normal distribution data among 3 groups.
Within group comparisons were performed using Student's t-test. Fisher
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groups. For the intention-to-treat analysis of echo and SPECT variables,
an analysis of covariance (ANCOVA) was performed to assess the differ-
ences between treatment groups at 6 and 12 months, after adjusting for
baseline values. Specifically, values at 6 and 12 months were taken as
the dependent variable and the associated baseline values and a factor
for treatment were taken as independent variables. Model adequacy
was assessed by examining the standardized residuals. The absolute
change of each value between 6 month (12 month) and baseline
were tested using ANOVA. Two-sided significance testing was used;
P value b 0.05 was deemed statistically significant.
3. Results
3.1. Enrollment and baseline characteristics
From 2011 February to 2012 March, 101 patients with an acute ST
segment elevation MI were screened, and 22 patients who fulfilled the
inclusion criteria were recruited. They were randomly assigned to
receive normoxia BMCs or hypoxia-preconditioned BMCs. Other 14 pa-
tients receiving standard treatment served as the control group (Fig. 1).
In the normoxia BMC group, one patient was excluded due to the pres-
ence of thrombus in the coronary artery prior to intracoronary infusion.
Successful intracoronary infusion of BMCs was performed in the re-
maining 21 patients. No patient was lost to follow-up during the study
period and the three groups were matched for baseline clinical charac-
teristics and concomitant pharmacologic therapy during the study, ex-
cept that more patients in the hypoxia-preconditioned group were
diabetic (Table 1).
3.2. Effect of hypoxia preconditioning on cell characteristics
Trypan blue staining revealed no significant difference in cell viabil-
ity between the normoxia and the hypoxia-preconditioned groupFig. 1. Study fl(96.4 ± 2.9% vs. 98.2 ± 1.7%, P = 0.18). The percentage of CD34+,
CD133+, CD309+, CD117+, CD29+, CD166+, mSca-1+ cells was
also similar in normoxia BMCs and hypoxia-preconditioned BMC
groups (Table 2).
3.3. Safety endpoints
There were no differences among three groups in the primary and
secondary safety endpoints with respect to the occurrence of MACEs
at 30 days and 1 year. Within the first 30 days, no patient in the
normoxia group, one patient in the hypoxia-preconditioned group and
two patients in control group died (0/11, 0%, 1/11, 9.1%, 2/14, 14.3%,
P = 0.76) (Table 3). No other adverse event was noted. During one-
year follow-up, MACEs occurred in 3/10 (30%) patients in the normoxia
group (hospitalization for heart failure, n = 3),1/11 (9.1%) patients in
the hypoxia-preconditioned group (hospitalization for heart failure,
n = 1; Target-vessel revascularization, n = 1) and no patient in
control group (Table 3). Specifically, no patient in three groups experi-
enced sustained ventricular tachycardia following 30 day and 1 year
follow-up.
3.4. Cardiac function and remodeling
Baseline LVEF, LVEDV and LVESVwere 56.9±12.4%, 115.2±42.5ml
and 55.1 ± 32.2 ml respectively in the normoxia group, 50.9 ± 12.9%,
136.9 ± 34.7 ml and 72.8 ± 32.8 ml respectively in the hypoxia-
preconditioned group and 57.1 ± 11.6%, 109.2 ± 19.7 ml and 48.8 ±
21.8 ml respectively in control group (Table 4). The WMSI was 1.3 ±
0.5, 1.5 ± 0.4 and 1.4 ±0.3 in the normoxia group, hypoxia-
preconditioned group and control group, respectively. There was signif-
icant improvement in change of LVEDV and LVESV in hypoxia-
preconditioned group both at 6 months and 12 months when com-
pared with normoxia group and control group, suggesting hypoxia-










Age, years 61.2 ± 12.8 59.7 ± 11.7 60.62 ± 10.85 0.96
Female 2 (18.2) 1 (9.1) 5 (35.7) 0.26
Killip-class
I 9 (81.8) 9 (81.8) 9 (64.29)
II 1 (9.1) 1 (9.1) 2 (14.29)
III 1 (9.1) 0 (0) 2 (14.29)
IV 0 (0) 1 (9.1) 1 (7.14) 0.81
Coronary artery disease
1-vessel 3 (27.3) 5 (45.5) 4 (28.57) 0.59
2-vessel 4 (36.4) 0 (0) 5 (35.71) 0.07
3-vessel 4 (36.4) 6 (54.6) 5 (35.71) 0.58
Infarct related artery
Left anterior descending 8 (73.7) 5 (45.5) 7 (50.00) 0.38
Right coronary artery 2 (18.2) 5 (45.5) 5 (35.71) 0.39
Left circumflex 1 (9.1) 1 (9.1) 2 (14.29) 0.89
Average time from symptom onset to PCI 6.11 ± 2.2 6.0 ± 2.4 5.77 ± 2.63 0.95
Stent number
0 4 (36.4) 3 (27.3) 3 (21.43)
1 5 (45.5) 7 (63.6) 11 (78.57)
2 2 (18.2) 1 (9.1) 0 (0) 0.41
Length of stent, mm 41.3 ± 26.3 36.4 ± 27.5 25.40 ± 5.87 0.28
Size of stent, mm 3.0 (3.0–54.0) 3.5 (3.0–4.0) 3.25 (3.00–3.50) 0.42
Blood biochemistry











Diabetes 0 (0) 5 (45.5) 2 (14.29) 0.03
Hypertension 5 (45.5) 5 (45.5) 6 (42.86) 0.99
Hyperlipidemia 5 (45.5) 3 (27.3) 2 (14.29) 0.22
Former or current smoking 7 (63.6) 10 (90.9) 7 (50.0) 0.10
Medications
Baseline
Aspirin 11 (100) 11 (100) 14 (100) /
Clopidogrel 11 (100) 11 (100) 14 (100) /
Statin 11 (100) 11 (100) 14 (100) /
ACEI 9 (81.8) 10 (90.9) 11 (78.57) 0.70
Beta-blocker 10 (90.9) 8 (72.7) 11 (78.57) 0.54
12-month N = 10 N = 10 N = 12
Aspirin 10 (100) 10 (100) 12 (100) /
Clopidogrel 10 (100) 10 (100) 12 (100) /
Statin 10 (100) 10 (100) 12 (100) /
ACEI 8 (80) 8 (80) 8 (66.7) 0.70
Beta-blocker 8 (80) 9 (90) 11 (91.7) 0.68
ACEI, Angiotensin-converting enzyme inhibitor; PCI, percutaneous coronary intervention
Data are means (SD), medium (range), or n (%) unless otherwise stated.
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the three groups in the change of LVEF and WMSI. Nonetheless
LVEF were significantly decreased at 6 months compared with baseline
in the control group (Table 4, P b 0.05), hypoxia-preconditioned BMC
therapy showed a trend of increased LVEF. WMSI were decreased at
6 months compared with baseline in the hypoxia-preconditioned group,
but not in the normoxia group (P b 0.05). At 12 months, WMSI wereTable 2






% Viability by Trypan blue
exclusion, mean ± SD
96.4 ± 2.9 98.2 ± 1.7 0.18
% of CD34 cells, mean ± SD 2.0 ± 1.9 2.5 ± 2.4 0.62
% of CD133 cells, mean ± SD 0.9 ± 1.0 1.0 ± 0.9 0.17
% of CD309 cells, mean ± SD 0.2 ± 0.2 0.2 ± 0.2 0.78
% of CD117 cells, mean ± SD 1.8 ± 1.7 5.1 ± 3.6 0.10
% of CD29 cells, mean ± SD 45.2 ± 30.6 53.0 ± 12.4 0.37
% of CD166 cells, mean ± SD 3.8 ± 5.0 1.8 ± 2.5 0.42
% of mSca-1 cells, mean ± SD, (n) 0.1 ± 0.2 0.3 ± 0.3 0.20
BMCs, bone marrow mononuclear cells.decreased both in the hypoxia-preconditioned group and the normoxia
group.
3.5. Quantitative variables of cardiac perfusion
SPECT imagingwas performed to evaluate myocardial perfusion fol-
lowing BMC administration (Table 5). At 6 months and 12 months,
there were no significant differences in the ratio of myocardium perfu-
sion defect among the three groups. Nonetheless the ratio of myocardi-
um perfusion defect was significantly decreased at 6 and 12 months in
the normoxia group. Similarly, there was a significant decrease in the
ratio of myocardium perfusion defect in the hypoxia-preconditioned
group. However, there was no significant decrease in the ratio of myo-
cardium perfusion defect at 6 and 12 months in the control group.
4. Discussion
To our knowledge, CHINA-AMI is the first-in-man trial to determine
the safety and feasibility of intracoronary administration of hypoxia-
preconditioned BMCs for treatment of acute ST segment elevation MI.
The results of this study demonstrate that administration of hypoxia-
preconditioned BMCs is comparable to that of normoxia BMCs in
Table 3








Before hospital discharge No. of patients
Death 0 0 0 /
Myocardial infarction 0 0 0 /
Sustained ventricular tachycardia 0 0 0 /
Stroke 0 0 0 /
Revascularization 0 0 0 /
1 month follow-up
Death 0 1 (9.1) 2 (14.3) 0.76
Myocardial infarction 0 0 0 /
Sustained ventricular tachycardia 0 0 0 /
Stroke 0 0 0 /
Rehospitalization for heart failure 0 0 0 /
Revascularization 0 0 0 /
Target-vessel revascularization 0 0 0 /
Stent thrombosis 0 0 0 /
Non-target-vessel revascularization 0 0 0 /
1 year follow-up
Death 0 0 0 /
Myocardial infarction 0 0 0 /
Sustained Ventricular tachycardia 0 0 0 /
Stroke 0 0 0 /
Rehospitalization for heart failure 3 (30.0) 1 (9.1) 0 0.055
Revascularization 0 0 0 /
Target-vessel revascularization 0 1 (9.1) 0 0.61
Stent thrombosis 0 0 0 /
Non-target-vessel revascularization 0 0 0 /
Total no. of SAEs 3 (30.0) 2 (18.2) 2 (14.3) 0.77
Total no. of AEs 5 (50.0) 4 (36.4) 6 (42.9) 0.91
a Fisher exact test.
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effect in terms of MACEs or proarrhythmia following administration of
hypoxia-preconditioned or normoxia BMCs. In both cell treated groups,
therewas significant improvement inmyocardial perfusion following ad-






Baseline 56.9 (12.4) 50.9 (12.9) 57.1 (11.6) 0.39
6 months 59.1 (7.0) 53.2 (14.2) 55.8 (8.4) 0.20
Absolute difference 0.4 (7.4) 1.6 (6.4) −4.9 (7.1)⁎ 0.08
12 months 56.8 (9.6) 56.1 (11.1) 59.6 (5.2) 0.73
Absolute difference 0.6 (7.2) 3.9 (6.5) −3.0 (8.9) 0.21
LVEDV
Baseline 115.2 (42.5) 136.9 (34.7) 109.2 (19.7) 0.14
6 months 96.4 (22.5) 104.2 (33.5) 105.7 (30.5) 0.13
Absolute difference −16.2 (31.6) −28.8 (37.9) 9.1 (17.3) 0.03
12 months 120.2 (49.9) 101.5 (24.6) 102.7 (47.0) 0.10
Absolute difference 6.9 (22.62) −30.5 (33.74)⁎ 17.8 (43.5) 0.04
LVESV
Baseline 55.1 (32.2) 72.8 (32.8) 48.8 (21.8) 0.16
6 months 40.3 (15.2) 54.0 (31.0) 48.0 (18.2) 0.04
Absolute difference −11.1 (20.8) −13.4 (16.1)⁎ 10.6 (14.4)⁎ 0.01
12 months 49.9 (34.4) 45.8 (18.1) 45.4 (25.8) 0.10
Absolute difference −6.8 (13.7) −23.6 (24.2)⁎ 16.8 (26.7) 0.01
WMSI
Baseline 1.3 (0.5) 1.5 (0.4) 1.4 (0.3) 0.69
6 months 1.1 (0.2) 1.2 (0.3) 1.2 (0.1) 0.97
Absolute difference −0.1 (0.1) −0.2 (0.2)⁎ −0.1 (0.2) 0.57
12 months 1.2 (0.3) 1.2 (0.3) 1.1 (0.1) 0.47
Absolute difference −0.1 (0.1)⁎ −0.2 (0.2)⁎ −0.2 (0.3) 0.33
LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVEDV,
left ventricular end-diastolic volume; WMSI, wall motion score index.
Data are means (SD) unless otherwise stated.
⁎ P b 0.05 versus baseline within the same group.by SPECT. Compared with the normoxia group or control, there was sig-
nificant improvement of LVDEVand LVESV at 6 and12months in hypoxia
preconditioned group. But there was no significant improvement in LVEF
after administration of hypoxia-preconditioned BMCs. Nevertheless, this
trial was not designed to compare the clinical efficacy of hypoxia-
preconditioned versus normoxia BMCs but to confirm the safety of
hypoxia-preconditioned BMCs.
Although BMC therapy has been a promising approach for MI treat-
ment, poor therapeutic efficacy still is the major issue.[1,2,18,19] A
Cochranemeta-analysis suggestedmild improvement in left ventricular
functionmeasured byMRI.[20] So efficacy optimization is the challenge
of stem cell therapy for MI. Prior experimental studies [11,21,22] have
shown that modification of BMCs, using gene transfer, drug pretreat-
ment and hypoxia preconditioning can enhance stem cell survival and
improve their therapeutic efficiency. Comparedwith genemodification,
hypoxia preconditioning of BMCs can be easily achieved by hypoxic cul-
ture and the potential risk associatedwith use of gene vectors is avoided
[11,12]. Our previous pre-clinical studies [11] have demonstrated that
hypoxia preconditioning can improve the therapeutic effect of BMCs
after MI in rats. Hypoxia preconditioning of BMCs increases their ex-
pression of pro-survival and proangiogenic factors including hypoxia-
inducible factor 1, angiopoietin-1, vascular endothelial growth factor
and its receptor, Flk-1, erythropoietin, Bcl-2, and Bcl-xL [11]. These cyto-
kines can further enhance the survival and therapeutic effects of BMCs.
The safety evaluation of hypoxia preconditioning is the first step to
forward this approach to clinical application. Thus, we choose safety
as the primary endpoint and it was evaluated by occurrence of major
adverse cardiovascular events in this study. It is reported that there
was no significant difference between the relative incidences of adverse
events comparing BMCs and control groups at three years [2]. Meta-
analysis also showed BMC therapy showed no difference with regards
to mortality events when compared to placebo [23]. Here we found
hypoxia-preconditioned BMC administration delivered by intracoronary
infusion in acute myocardial infarction patients also demonstrated safety
with one year follow-up. The adverse events of hypoxia-preconditioned
BMC therapy were similar with normoxia or control group. These results
provide the basis for further large size study of this hypoxia precondition-
ing approach.
In this study, SPECT revealed that both normoxia and hypoxia-
preconditioned BMCs significantly improved myocardial perfusion as
determined by the reduced ratio of myocardium perfusion defect
compared with baseline. Nevertheless, there was significant improve-
ment of LVEDV and LVESV change in hypoxia group compared with
normoxia and control groups. These findings suggest that although
both types of BMCs can enhance myocardial perfusion following MI,
hypoxia-preconditioned BMCs seem to be more effective in ameliora-
tion of adverse LV remodeling afterMI. Nonetheless the trialwas not de-
signed to compare the clinical efficacy of hypoxia-preconditioned
versus normoxia BMCs. Moreover, BMC therapy appears to be more ef-
fective in patients with severely impaired LV function after MI. In this
study, patients recruited into the trial had only moderately reduced
LVEF. Thismight account for themodest improvement in LVEF observed
in this study. Therefore, further studies should be targeted to those pa-
tients with severely impaired LVEF. More importantly, the clinical effi-
cacy of hypoxia-preconditioned BMCs will be addressed in the future
phase II–III prospective randomized clinical trial in a larger cohort of
patients.5. Limitations
There are limitations to this study. First, the number of patients re-
cruited in this pilot trial was small. Our results can only provide some ini-
tial assessment of the safety and feasibility of hypoxia-preconditioned
BMCs. Second, the function of hypoxia-preconditioned and normoxia
BMCs was not investigated.
Table 5
Quantitative of myocardium perfusion defect score by SPECT.
Variables Normoxia Hypoxia-preconditioned Control P value
Ratio of myocardium perfusion defect
Baseline 26.9 (9.1) 27.3 (14.5) 27.9 (7.0) 0.98
6 months 20.8 (9.4) 22.4 (13.9) 26.2 (8.4) 0.10
Absolute difference −6.1 (4.1)⁎ −4.9 (5.6)⁎ −1.7 (3.7) 0.10
12 months 21.3 (8.0) 20.4 (12.4) 25.0 (10.7) 0.49
Absolute difference −5.9 (4.3)⁎ −3.4 (6.4) −2.6 (5.0) 0.46
Data are means (SD) unless otherwise stated.
⁎ P b 0.05 versus baseline within the same group.
451X. Hu et al. / International Journal of Cardiology 184 (2015) 446–4516. Conclusion
In conclusion, our results provide the first-in-man evidence that
intracoronary administration of hypoxia-preconditioned autologous
BMCs following acute MI appears to be safe and feasible. These results
provide the basis for future prospective randomized clinical trials in a
larger patient cohort.
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